بررسی وضعیت مدیریت مبتنی بر شواهد ارزشیابی اقتصادی در حوزه دارو نظام سلامت ایران و کشورهای منتخب: مطالعه تطبیقی
الموضوعات :ابوالفضل علیاری 1 , شقایق وحدت 2 , سعاد محفوظ پور 3 , حسین مشیری تبریزی 4
1 - دانشجوی دکتری مدیریت خدمات بهداشتی درمانی، واحد تهران جنوب، دانشگاه آزاد اسلامی، تهران، ایران
2 - استادیار، مدیریت خدمات بهداشتی درمانی، واحد تهران جنوب، دانشگاه آزاد اسلامی، تهران، ایران
3 - دانشیار، مدیریت خدمات بهداشتی درمانی، واحد تهران جنوب، دانشگاه آزاد اسلامی، تهران، ایران
4 - استادیار، مدیریت خدمات بهداشتی درمانی، واحد تهران جنوب، دانشگاه آزاد اسلامی، تهران، ایران
الکلمات المفتاحية: مدیریت مبتنی بر شواهد, ارزشیابی اقتصادی, نظام سلامت, دارو,
ملخص المقالة :
مقدمه: امروزه در سطح بین المللی بهره‌گیری از شواهد در تصمیم‌گیری در زمینه سیاست‌گذاری و برنامه‌ریزی بخش سلامت و دارو امری ضروری است. لذا این پژوهش با هدف مقایسه وضعیت مدیریت مبتنی بر شواهدارزشیابی اقتصادی در حوزه دارو درنظام سلامت ایران و کشورهای منتخب انجام گردید. روش پژوهش: این پژوهش، یک مطالعه تطبیقی است که در سال 1401 انجام شد. در این مطالعه، نمونه‌گیری به صورت هدفمند بوده و کشورهای استرالیا، انگلستان، آلمان و کانادا به لحاظ مولفه‌های استفاده از شواهد در ازرشیابی اقتصادی حوزه دارو مورد مقایسه قرارگرفتند. برای گردآوری داده‌ها از پایگاه‌های اطلاعاتی معتبر و سایر منابع مرتبط در زمینه موضوع پژوهش استفاده شد. در این مطالعه، یافته‌های به دست آمده در قالب جدول تطبیقی مورد مقایسه قرارگرفتند. یافته‌ها: یافته‌ها نشان داد که تولید و استخراج شواهد در کشورهای کانادا، انگلستان و استرالیا الزامی و در کشور ایران و آلمان اختیاری است. هم‌چنین نتایج نشان داد که به جزء کشور استرالیا و کانادا در سایر کشورهای دیگر از شواهد برای افزدون داروها به لیست دارویی استفاده نمی‌شود و در همه کشورها نیز به جزء کشور ایران، استانداردها و چارچوب‌های تولید شواهد وجود دارد. نتیجه‌گیری: براساس نتایج پژوهش، طراحی مدل یکپارچه در جهت کاهش موازی کاری، توسعه ارتباطات با پژوهشگران و مراکز تحقیقاتی، تعیین اصول و مقررات تولید و به کارگیری شواهدات، تقویت رهبری، مدیریت و تولیت نظام سلامت متناسب با وضعیت کشور و سایر کشورهای با شرایط مشابه پیشنهاد می‌گردد.
1- Gröne O, Garcia-Barbero M. Integrated care: a position paper of the WHO European office for integrated health care services. International journal of integrated care, 2001;1.
2- Organization WH. Choosing Interventions that are Cost-Effective (WHO-CHOICE). Geneva: World Health Organization; 2012.
3- Yan R. Cost-effective Intervention: Innovative Strategies for Public Health Care: Pennsylvania State University; 2014.
4- Weinstein MC, Skinner JA. Comparative effectiveness and health care spending—implications for reform. New England Journal of Medicine, 2010; 362(5): 460-5.
5- GROL R. Between evidence-based practice and total quality management: the implementation of cost-effective care. International Journal for Quality in Health Care, 2000; 12(4): 297-304.
6- Harrison S. The politics of evidence-based medicine in the United Kingdom. Policy & Politics, 1998; 26(1): 15-31.
7- García Del Junco J, De Reyna Zaballa R, García Álvarez de Perea J. Evidence-based administration for decision making in the framework of knowledge strategic management. The Learning Organization, 2010; 17(4): 343-63.
8- Walshe K, Rundall TG. Evidence-based management: From theory to practice in health care. The Milbank Quarterly, 2001; 79(3): 429-57.
9- Kovner AR, Fine DJ, D'Aquila R. Evidence-based management in healthcare: Health Administration Press; 2009.
10- White KR, Lemak CH, Griffith JR. Improving healthcare management education using principles from Baldrige and evidence-based management. Journal of Health Administration Education, 2011; 28(3): 187-207.
11- Hofmann PBDF. The Ethics of Evidence-Based Management. Healthcare Executive, 2010; 25(1): 48-51.
12- Stewart R. Evidence-based management: a practical guide for health professionals: Radcliffe Publishing; 2002.
13- Hamlin B. In Support of Evidence-Based Healthcare Management: an empirical study of managerial effectiveness within an NHS trust hospital: Management Research Centre, Wolverhampton Business School; 2001.
14- Hewison A. Evidence-based management in the NHS: is it possible? Journal of Health Organization and Management, 2004; 18(5): 336-48.
15- Muir Gray J. Evidence-based healthcare: how to make health policy and management decisions. London: Churchill Livingstone, 1997; 53.
16- Asante AD, Zwi AB. Factors influencing resource allocation decisions and equity in the health system of Ghana. Public Health, 2009; 123(5): 371-7.
17- Manning J. Exceptional circumstances schemes and the social factors exclusion in healthcare rationing. Oxford University Commonwealth Law Journal, 2013; 13(1): 75-114.
18- Samanta A, Samanta J. Evidence-based medicine: A clinical governance tool for rationalising or rationing health care? Clinical Governance: An International Journal, 2005; 10(4): 308-13.
19- Buse K, Mays N, Walt G. Making health policy: McGraw-Hill Education (UK); 2012.
20- Bastani P, Kavosi Z, Poori SA, Nasab MHI. Evidence-based policy and decision-making among health managers: a case of Shiraz University of Medical Sciences. Galen Medical Journal, 2017; 6(1): 30-8.
21- Packer M, Metra M. Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020; 22(10): 1759-67.
22- Imani Nasab MH, Seyedin SH, Majdzadeh SR, Yazdizadeh B, Salehi M. Factors Affecting the Development of Evidence-Based Health Policy Papers at the Ministry of Health Care and Medical Education. Journal of Health Administration, 2015; 18(60): 105-17.
23- Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? Journal of Medical Economics, 2007; 10(3): 325-37.
24- Chalkidou K, Culyer AJ. Making choices on the journey to universal health care coverage: from advocacy to analysis. Value in Health, 2016; 19(8): 910-2.
25- Hammad EA. The use of economic evidence to inform drug pricing decisions in Jordan. Value in Health, 2016; 19(2): 233-8.
26- Rabarison KM, Bish CL, Massoudi MS, Giles WH. Economic evaluation enhances public health decision making. Frontiers in public health, 2015; 3: 164.
27- Evers S, Salvador–Carulla L, Halsteinli V, McDaid D, Group M. Implementing mental health economic evaluation evidence: building a bridge between theory and practice. Journal of Mental Health, 2007; 16(2): 223-41.
28- Gumbs PD, Verschuren MW, Mantel-Teeuwisse AK, de Wit AG, de Boer A, Klungel OH. Economic Evaluations of Cholesterol-Lowering Drugs. Pharmacoeconomics, 2007; 25(3): 187-99.
29- Grosios K, Gahan PB, Burbidge J. Overview of healthcare in the UK. EPMA Journal, 2010; 1(4): 529-34.
30- Macarthur D. Pharmaceutical pricing and reimbursement in the United Kingdom. HEPAC Health Economics in Prevention and Care, 2000; 1(1): 47-50.
31- Healy J, Sharman E, Lokuge B, Organization WH. Australia: Health system review; 2006.
32- Armstrong BK, Gillespie JA, Leeder SR, Rubin GL, Russell LM. Challenges in health and health care for Australia. Medical Journal of Australia, 2007; 187(9): 485-9.
33- Barati Marnani A, Nabilo B. AComparative study of the organizational superiority model in Health care at selected countries proposing a model for Iran. Journal of Health Administration, 2005; 7(18): 14-9.
34- Ahmadi m, jalali r, Raiszadeh m. Seven years of experience in the health system transformation plan in Iran: a comparative study and narrative review. Quarterly Journal of Nersing Management, 2021; 10(1): 119-29.
35- Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. Materia socio-medica, 2012; 24(2): 112.
36- Busse R, Riesberg A, Organization WH. Health care systems in transition: Germany; 2004.
37- Marchildon GP, Allin S, Merkur S. Canada: Health system review. Health Systems in Transition, 2020; 22(3).
38- Riedel R, Repschläger U, Griebenow R, Breitkopf S, Schmidt S, Guhl A. International standards for health economic evaluation with a focus on the German approach. Journal of clinical pharmacy and therapeutics, 2013; 38(4): 277-85.
39- Stevens A. Pharmaceutical pricing and reimbursement policies in Australia. mimeo; 2000.
40- Haas M, Viney R, Gallego G. Implementing guidelines for reimbursement in Australia: how the PBAC and MSAC use comparative cost-effectiveness. Sydney (NSW): Centre for Health Economics (CHERE)/University of Technology Sydney; 2006.
41- Miners JO, Rowland A, Novak JJ, Lapham K, Goosen TC. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacology & Therapeutics, 2021; 218: 107.
42- Wood K, Giannopoulos V, Louie E, Baillie A, Uribe G, Lee KS, et al. The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: A systematic review. Implementation Research and Practice, 2020; 1: 262.
43- Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016; 120(10): 1104-14.
44- Tay Wee Teck JB, Baldacchino A. Why Do Different Forms of Knowledge Matter in Evidence-Based Drug Policy? : American Public Health Association; 2022: S140-S2.
45- Paris V, Docteur E. Pharmaceutical pricing and reimbursement policies in Germany; 2008.
46- Danzon PM, Ketcham JD, editors. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Forum for health economics & policy; 2004: De Gruyter.
47- Vandersluis S, Reid JC, Orlando L, Bhatia M. Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. Drug Discovery Today; 2022: 103407.
48- Wenzl M, Paris V. Pharmaceutical reimbursement and pricing in Germany. OECD (Ed), 2018;1:22.
49- Paris V, Belloni A. Value in pharmaceutical pricing. 2013.
50- Masoudi Asl I, Hasanzadeh E, Raeissi p. Determining the Sources of Evidence Used in Decision Making of Staff Managers in Iran University of Medical Sciences:2019. Journal of Health Administration, 2021; 23(4): 61-9.
_||_1- Gröne O, Garcia-Barbero M. Integrated care: a position paper of the WHO European office for integrated health care services. International journal of integrated care, 2001;1.
2- Organization WH. Choosing Interventions that are Cost-Effective (WHO-CHOICE). Geneva: World Health Organization; 2012.
3- Yan R. Cost-effective Intervention: Innovative Strategies for Public Health Care: Pennsylvania State University; 2014.
4- Weinstein MC, Skinner JA. Comparative effectiveness and health care spending—implications for reform. New England Journal of Medicine, 2010; 362(5): 460-5.
5- GROL R. Between evidence-based practice and total quality management: the implementation of cost-effective care. International Journal for Quality in Health Care, 2000; 12(4): 297-304.
6- Harrison S. The politics of evidence-based medicine in the United Kingdom. Policy & Politics, 1998; 26(1): 15-31.
7- García Del Junco J, De Reyna Zaballa R, García Álvarez de Perea J. Evidence-based administration for decision making in the framework of knowledge strategic management. The Learning Organization, 2010; 17(4): 343-63.
8- Walshe K, Rundall TG. Evidence-based management: From theory to practice in health care. The Milbank Quarterly, 2001; 79(3): 429-57.
9- Kovner AR, Fine DJ, D'Aquila R. Evidence-based management in healthcare: Health Administration Press; 2009.
10- White KR, Lemak CH, Griffith JR. Improving healthcare management education using principles from Baldrige and evidence-based management. Journal of Health Administration Education, 2011; 28(3): 187-207.
11- Hofmann PBDF. The Ethics of Evidence-Based Management. Healthcare Executive, 2010; 25(1): 48-51.
12- Stewart R. Evidence-based management: a practical guide for health professionals: Radcliffe Publishing; 2002.
13- Hamlin B. In Support of Evidence-Based Healthcare Management: an empirical study of managerial effectiveness within an NHS trust hospital: Management Research Centre, Wolverhampton Business School; 2001.
14- Hewison A. Evidence-based management in the NHS: is it possible? Journal of Health Organization and Management, 2004; 18(5): 336-48.
15- Muir Gray J. Evidence-based healthcare: how to make health policy and management decisions. London: Churchill Livingstone, 1997; 53.
16- Asante AD, Zwi AB. Factors influencing resource allocation decisions and equity in the health system of Ghana. Public Health, 2009; 123(5): 371-7.
17- Manning J. Exceptional circumstances schemes and the social factors exclusion in healthcare rationing. Oxford University Commonwealth Law Journal, 2013; 13(1): 75-114.
18- Samanta A, Samanta J. Evidence-based medicine: A clinical governance tool for rationalising or rationing health care? Clinical Governance: An International Journal, 2005; 10(4): 308-13.
19- Buse K, Mays N, Walt G. Making health policy: McGraw-Hill Education (UK); 2012.
20- Bastani P, Kavosi Z, Poori SA, Nasab MHI. Evidence-based policy and decision-making among health managers: a case of Shiraz University of Medical Sciences. Galen Medical Journal, 2017; 6(1): 30-8.
21- Packer M, Metra M. Guideline‐directed medical therapy for heart failure does not exist: a non‐judgmental framework for describing the level of adherence to evidence‐based drug treatments for patients with a reduced ejection fraction. European Journal of Heart Failure, 2020; 22(10): 1759-67.
22- Imani Nasab MH, Seyedin SH, Majdzadeh SR, Yazdizadeh B, Salehi M. Factors Affecting the Development of Evidence-Based Health Policy Papers at the Ministry of Health Care and Medical Education. Journal of Health Administration, 2015; 18(60): 105-17.
23- Chisholm D, Evans DB. Economic evaluation in health: saving money or improving care? Journal of Medical Economics, 2007; 10(3): 325-37.
24- Chalkidou K, Culyer AJ. Making choices on the journey to universal health care coverage: from advocacy to analysis. Value in Health, 2016; 19(8): 910-2.
25- Hammad EA. The use of economic evidence to inform drug pricing decisions in Jordan. Value in Health, 2016; 19(2): 233-8.
26- Rabarison KM, Bish CL, Massoudi MS, Giles WH. Economic evaluation enhances public health decision making. Frontiers in public health, 2015; 3: 164.
27- Evers S, Salvador–Carulla L, Halsteinli V, McDaid D, Group M. Implementing mental health economic evaluation evidence: building a bridge between theory and practice. Journal of Mental Health, 2007; 16(2): 223-41.
28- Gumbs PD, Verschuren MW, Mantel-Teeuwisse AK, de Wit AG, de Boer A, Klungel OH. Economic Evaluations of Cholesterol-Lowering Drugs. Pharmacoeconomics, 2007; 25(3): 187-99.
29- Grosios K, Gahan PB, Burbidge J. Overview of healthcare in the UK. EPMA Journal, 2010; 1(4): 529-34.
30- Macarthur D. Pharmaceutical pricing and reimbursement in the United Kingdom. HEPAC Health Economics in Prevention and Care, 2000; 1(1): 47-50.
31- Healy J, Sharman E, Lokuge B, Organization WH. Australia: Health system review; 2006.
32- Armstrong BK, Gillespie JA, Leeder SR, Rubin GL, Russell LM. Challenges in health and health care for Australia. Medical Journal of Australia, 2007; 187(9): 485-9.
33- Barati Marnani A, Nabilo B. AComparative study of the organizational superiority model in Health care at selected countries proposing a model for Iran. Journal of Health Administration, 2005; 7(18): 14-9.
34- Ahmadi m, jalali r, Raiszadeh m. Seven years of experience in the health system transformation plan in Iran: a comparative study and narrative review. Quarterly Journal of Nersing Management, 2021; 10(1): 119-29.
35- Ridic G, Gleason S, Ridic O. Comparisons of health care systems in the United States, Germany and Canada. Materia socio-medica, 2012; 24(2): 112.
36- Busse R, Riesberg A, Organization WH. Health care systems in transition: Germany; 2004.
37- Marchildon GP, Allin S, Merkur S. Canada: Health system review. Health Systems in Transition, 2020; 22(3).
38- Riedel R, Repschläger U, Griebenow R, Breitkopf S, Schmidt S, Guhl A. International standards for health economic evaluation with a focus on the German approach. Journal of clinical pharmacy and therapeutics, 2013; 38(4): 277-85.
39- Stevens A. Pharmaceutical pricing and reimbursement policies in Australia. mimeo; 2000.
40- Haas M, Viney R, Gallego G. Implementing guidelines for reimbursement in Australia: how the PBAC and MSAC use comparative cost-effectiveness. Sydney (NSW): Centre for Health Economics (CHERE)/University of Technology Sydney; 2006.
41- Miners JO, Rowland A, Novak JJ, Lapham K, Goosen TC. Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacology & Therapeutics, 2021; 218: 107.
42- Wood K, Giannopoulos V, Louie E, Baillie A, Uribe G, Lee KS, et al. The role of clinical champions in facilitating the use of evidence-based practice in drug and alcohol and mental health settings: A systematic review. Implementation Research and Practice, 2020; 1: 262.
43- Salas-Vega S, Bertling A, Mossialos E. A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Health Policy, 2016; 120(10): 1104-14.
44- Tay Wee Teck JB, Baldacchino A. Why Do Different Forms of Knowledge Matter in Evidence-Based Drug Policy? : American Public Health Association; 2022: S140-S2.
45- Paris V, Docteur E. Pharmaceutical pricing and reimbursement policies in Germany; 2008.
46- Danzon PM, Ketcham JD, editors. Reference pricing of pharmaceuticals for Medicare: evidence from Germany, The Netherlands, and New Zealand. Forum for health economics & policy; 2004: De Gruyter.
47- Vandersluis S, Reid JC, Orlando L, Bhatia M. Evidence-based support for phenotypic drug discovery in acute myeloid leukemia. Drug Discovery Today; 2022: 103407.
48- Wenzl M, Paris V. Pharmaceutical reimbursement and pricing in Germany. OECD (Ed), 2018;1:22.
49- Paris V, Belloni A. Value in pharmaceutical pricing. 2013.
50- Masoudi Asl I, Hasanzadeh E, Raeissi p. Determining the Sources of Evidence Used in Decision Making of Staff Managers in Iran University of Medical Sciences:2019. Journal of Health Administration, 2021; 23(4): 61-9.
